|
KMID : 1030220210220020113
|
|
Journal of Korean Diabetes
2021 Volume.22 No. 2 p.113 ~ p.125
|
|
|
Recent Advances in Sodium Glucose Cotransporter-2 Inhibitors
|
|
Cho Dong-Hyeok
|
|
|
Abstract
|
|
|
|
Sodium glucose cotransporter-2 inhibitors (SGLT2i) block SGLT2 in the renal proximal tubule and increase the excretion of glucose into the urine, thereby decreasing serum glucose concentrations. These glucose-lowering effects are independent of insulin action. SGLT2i has been demonstrated to reduce cardiovascular complications and hospitalization for heart failure. SGLT2i has also shown remarkable inhibition effects on the progression of renal complications, decreasing serum creatinine, reducing albuminuria, and decreasing death from renal disease. These cardiorenal protective effects appear to be independent of glycemic control efficacy, and in view of these results, SGLT2i is recommended in type 2 diabetes patients at high risk of cardiovascular or renal disease. This review aims to provide an update on the mechanisms, efficacy, cardiorenal protective effects, and adverse effects of SGLT2i.
|
|
|
KEYWORD
|
|
|
Antagonists & inhibitors, Cardiovascular diseases, Diabetes mellitus, type 2, Hypoglycemic agents, Sodium-glucose transport proteins
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|